股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 先瑞達醫療科技控股有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06669 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 10,000,000,000 | | USD | | 0.00001 | USD | | 100,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 10,000,000,000 | USD | | 0.00001 | USD | | 100,000 | ...

Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號 : 6669) N O T I F I C AT I O N L E T T E R Dear non-registered shareholder(s), 24 September 2025 Acotec Scientific Holdings Limited (the "Company") – Notice of Publication of 2025 Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the web ...

Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號 : 6669) N O T I F I C AT I O N L E T T E R 24 September 2025 Dear registered shareholders, Acotec Scientific Holdings Limited (the "Company") – Notice of Publication of 2025 Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website o ...

Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 (Incorporated in the Cayman Islands with limited liability) 股Sto 份ck C代 號：ode : 6669 6669 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 中期報告 2025 目錄 | 公司資料 | 2 | | --- | --- | | 財務概要 | 4 | | 管理層討論及分析 | 5 | | 其他資料 | 26 | | 獨立核數師審閱報告 | 32 | | 綜合損益表 | 33 | | 綜合損益及其他全面收益表 | 34 | | 綜合財務狀況表 | 35 | | 綜合權益變動表 | 37 | | 簡明綜合現金流量表 | 39 | | 未經審核中期財務報告附註 | 40 | | 釋義 | 58 | 公司資料 董事會 執行董事 李靜女士 （董事會主席） 非執行董事 Silvio Rudolf SCHAFFNER先生 Arthur Crosswell BUTCHER先生 June CHANG女士 獨立非執行董事 王玉琦醫師 倪 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 先瑞達醫療科技控股有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 第 1 頁 共 10 頁 v 1.1.1 FF301 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06669 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 10,000,000,000 | USD | | 0.00001 | USD | | 100,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | 10,000,000,000 | USD | | 0.00001 | USD | | 10 ...

Summary of Xianruida Medical Conference Call Company Overview - **Company**: Xianruida Medical - **Industry**: Medical Devices, specifically focusing on drug-coated balloons (DCB) and related products Key Financial Performance - **Revenue**: Achieved 351 million yuan in H1 2025, a year-on-year increase of 20.1% [3] - **Net Profit**: Increased by 121% to 88.58 million yuan, with a net profit margin of 25% [2][3] - **Gross Margin**: Maintained at a high level of 74.2% [2][3][25] Product Development and Market Expansion - **Product Approvals**: Over 9 new products approved in 2025, including the first vertebral artery drug balloon [18][27] - **Clinical Trials**: The first Xisha drug balloon is undergoing IDE clinical trials in the US [2][4] - **International Expansion**: Registered in over 20 countries and initiated 41 new country registration projects [2][4][5] - **Partnerships**: Collaboration with Boston Scientific (波科) for distribution agreements in Europe and joint product development [2][7] Cost Control and Operational Efficiency - **Cost Management**: Reduced R&D expense ratio from 34% to 29% and sales expense ratio from 16% to 11% [2][6] - **Production Optimization**: Implemented measures such as using self-produced raw materials to replace external sourcing, enhancing operational efficiency [6][23] Market Trends and Product Performance - **Peripheral DCB Products**: Contributed 176 million yuan in revenue, indicating rapid growth [3] - **Domestic Market Share**: Achieved a 30% market share in lower limb drug balloon products, with increasing usage in hospitals [2][10] - **Clinical Data**: Vertebral artery drug balloon showed a 12-month target lesion revascularization rate of only 13.04%, significantly lower than the control group [4][15] Future Outlook and Strategic Focus - **Revenue Guidance**: Full-year revenue guidance adjusted to a growth of 20%-25%, with net profit target raised to 120 million yuan [4][24] - **Product Pipeline**: Focus on expanding product lines, enhancing innovation speed, and deepening international partnerships [8][9] - **R&D Investment**: Continued emphasis on R&D to maintain industry leadership and explore new treatment areas [29][30] Regulatory and Market Challenges - **Collective Procurement Impact**: Current gross margin is expected to remain stable despite potential impacts from collective procurement policies [25][26] - **Market Competition**: Despite the emergence of over 20 competitors, the company maintains a leading position in the market [13] Conclusion - **Competitive Advantage**: Xianruida Medical's focus on innovation, market expansion, and operational efficiency positions it well for future growth despite a complex market environment [39][40]

消息面上，先瑞达医疗发布中期业绩，上半年收入3.51亿元人民币，同比增加20.1%；期内溢利8857.7 万元，同比增加121.7%。此外，公司收到中国国家药品监督管理局对外周可控机械解脱带纤维毛弹簧 圈的注册批准。该产品用于外周血管的动脉瘤、动静脉畸形和动静脉瘘的填塞。公司将适时在中国开展 营销活动。 公开资料显示，2022年12月，先瑞达医疗发布公告称，波士顿科学向公司先瑞达发起要约收购，以每股 20港元的价格交易先瑞达不超过65%股份的多数股权，预计交易金额约为5.23亿美元，完成交易后，波 科成为先瑞达医疗的控股公司。2023年7月，双方签订了合作框架协议和服务框架协议，双方将在产品 全球商业化、产品制造服务和产品研发等领域开展合作。 先瑞达医疗-B(06669)绩后涨超13%，截至发稿，涨9.81%，报12.42港元，成交额1101.11万港元。 ...

Core Viewpoint - Xianruida Medical-B (06669) experienced a significant stock price increase of over 13% following the release of its interim results, indicating positive market sentiment towards the company's performance and future prospects [1] Financial Performance - The company reported a revenue of 351 million RMB for the first half of the year, representing a year-on-year increase of 20.1% [1] - Net profit for the same period was 88.577 million RMB, showing a substantial year-on-year growth of 121.7% [1] Regulatory Approval - Xianruida Medical received registration approval from the National Medical Products Administration of China for its peripheral controllable mechanical release fiber spring ring, which is intended for use in treating peripheral vascular aneurysms, arteriovenous malformations, and arteriovenous fistulas [1] - The company plans to initiate marketing activities in China for this product in a timely manner [1] Strategic Developments - In December 2022, Boston Scientific initiated a takeover bid for Xianruida Medical, offering 20 HKD per share for up to 65% of the company's majority stake, with an estimated transaction value of approximately 523 million USD [1] - In July 2023, both parties signed a cooperation framework agreement and service framework agreement to collaborate on global commercialization, manufacturing services, and product development [1]

Core Insights - The company reported a revenue of 351 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 20.1% [1] - The profit for the period was 88.577 million RMB, which is a significant year-on-year increase of 121.7% [1] - The basic earnings per share were 0.29 RMB [1]

Group 1 - The company reported a revenue of 351 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 20.1% [1] - Gross profit for the same period was 260 million RMB, showing a year-on-year growth of 19.9% [1] - The net profit for the period reached 88.58 million RMB, which is a significant year-on-year increase of 121.7% [1]